The effectiveness of erysipelas prophylaxis depends on the cumulative dose of benzathine penicillin G.
Benzathine penicillin G
Cumulative dose
Erysipelas
Recurrence
Journal
Dermatology reports
ISSN: 2036-7392
Titre abrégé: Dermatol Reports
Pays: Italy
ID NLM: 101566470
Informations de publication
Date de publication:
14 Sep 2022
14 Sep 2022
Historique:
received:
28
11
2021
accepted:
04
12
2021
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
7
10
2022
Statut:
epublish
Résumé
Erysipelas is an acute infection due to S. pyogenes and is characterized by a high risk of relapses. The number of patients suffering from one or more recurrences varied depending on the study and accounted for between 16% and 47% of the total number of those affected. Antibiotic prophylaxis with the use of penicillin can reduce the risk of recurrence by 47%. A number of 873 patients with erysipelas treated at the Hospital for Infectious Diseases in Warsaw from 2010 to 2018 was enrolled in the study. Benzathine-penicillin G was given intramuscularly at a dose of 1.2 MU or 2.4 MU or 3.6 MU. The earliest moment that prophylactic treatment was administered was the first episode of erysipelas recurrence. The decision to administer the antibiotic and the dose to use was discretionally made by the examining physician. Altogether 104 (11.9%) persons experienced at least one episode of erysipelas recurrence during the study period. A total of 2976 doses of benzathine- penicillin G (BP) were administered. The most common dose was that of 2.4 MU (2380, 80%). The dose of 1.2 MU was given 567 times (19%). The highest dose,
Identifiants
pubmed: 36199905
doi: 10.4081/dr.2022.9429
pmc: PMC9527694
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9429Informations de copyright
©Copyright: the Author(s).
Déclaration de conflit d'intérêts
Conflict of interest: The authors declare no potential conflict of interest.
Références
J Infect. 2014 Jul;69(1):26-34
pubmed: 24576824
Br J Dermatol. 2012 Jan;166(1):169-78
pubmed: 21910701
J Microbiol Immunol Infect. 2017 Oct;50(5):613-618
pubmed: 26475200
Acta Otorhinolaryngol Ital. 2007 Feb;27(1):27-32
pubmed: 17601208
N Engl J Med. 2013 May 2;368(18):1695-703
pubmed: 23635049
Curr Infect Dis Rep. 2014 Sep;16(9):422
pubmed: 24980389
Dermatology. 2007;215(2):118-22
pubmed: 17684373
J Dermatolog Treat. 2018 Feb;29(1):39-43
pubmed: 28489486
Neth J Med. 2007 Mar;65(3):89-94
pubmed: 17387234
Dermatology. 2007;214(1):52-7
pubmed: 17191048
J Eur Acad Dermatol Venereol. 2006 Aug;20(7):818-22
pubmed: 16898904
Infection. 1987 Mar-Apr;15(2):105-6
pubmed: 3110071
Diabetes Care. 2018 Mar;41(3):513-521
pubmed: 29330152
Antimicrob Agents Chemother. 2014 Nov;58(11):6735-41
pubmed: 25182635
Cochrane Database Syst Rev. 2017 Jun 20;6:CD009758
pubmed: 28631307
Open Access Maced J Med Sci. 2019 Mar 15;7(6):937-942
pubmed: 30976336